These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 15134822)

  • 21. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
    Aaronson K
    Health News; 2003 May; 9(5):4. PubMed ID: 12739453
    [No Abstract]   [Full Text] [Related]  

  • 24. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
    Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of a selective aldosterone blocker in mice with chronic heart failure.
    Wang D; Liu YH; Yang XP; Rhaleb NE; Xu J; Peterson E; Rudolph AE; Carretero OA
    J Card Fail; 2004 Feb; 10(1):67-73. PubMed ID: 14966777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
    Urabe A; Izumi T; Abe Y; Taniguchi I; Mochizuki S
    Hypertens Res; 2006 Aug; 29(8):627-34. PubMed ID: 17137219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
    Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
    Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplerenone--a novel selective aldosterone blocker.
    Zillich AJ; Carter BL
    Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
    Yasuoka S; Kai H; Kajimoto H; Kudo H; Takayama N; Anegawa T; Koga M; Miyamoto T; Mifune H; Kage M; Hirooka Y; Imaizumi T
    Circ J; 2013; 77(6):1474-81. PubMed ID: 23470864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
    Thohan V; Torre-Amione G; Koerner MM
    Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
    Dawson A; Davies JI; Struthers AD
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):29-36. PubMed ID: 15038411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
    Takeda Y
    Hypertens Res; 2009 May; 32(5):321-4. PubMed ID: 19300447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
    Galuppo P; Bauersachs J
    Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
    Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactions of high salt intake and the response of the cardiovascular system to aldosterone.
    Conlin PR
    Cardiol Rev; 2005; 13(3):118-24. PubMed ID: 15831143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of aldosterone receptor blockade in the management of cardiovascular disease.
    Liew D; Krum H
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
    Verma A; Solomon SD
    Curr Heart Fail Rep; 2007 Dec; 4(4):183-9. PubMed ID: 18221614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.